Pharmacological evaluation of tannic acid–based chelation therapy in ferric citrate–supplemented rats

Tannic acid is recognised as a natural iron chelator; however, its in vivo applicability may be constrained by non-specific interactions with amino- and thiol-containing biomolecules, potentially altering its bioavailability, pharmacokinetics and pharmacodynamics. In the present study, several formulations of tannic acid (TA)–based chelators, including unmodified TA, oxidised TA (TAox), phenylalanine-combined TA (TAphe), lysine-combined TA (TAlys), or cysteine-combined TA (TAcys), were synthesized and evaluated for chelation therapy in ferric citrate–supplemented rats. Animals fed a ferric citrate–enriched diet for eight weeks, followed by an eight-week chelation regimen with distinct TA-based formulations, exhibited chelator-dependent alterations in hepatic iron accumulation and liver enzyme activity, without significant changes in reactive oxygen species (ROS) production or lipid peroxidation. Notably, TAlys exhibited the greatest reduction in hepatic iron, while TAcys exhibited the greatest attenuation of serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) activities. In plasma, selected chelation treatments, particularly TAphe, reduced plasma ROS levels without affecting systemic iron accumulation. In contrast, none of the TA-based chelation treatments produced statistically significant changes in brain iron levels or oxidative stress markers, although some trends in specific behavioral performance were observed. Collectively, these findings indicate that TA-based chelation therapy predominantly modulates iron homeostasis and function. Specific TA-based formulations may therefore represent promising candidates for further pharmacological development in targeted iron chelation and related therapeutic or nutraceutical applications.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-19
DOI
https://doi.org/10.1038/s41598-026-78933-0
Primary Topic
Iron Metabolism and Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacological evaluation of tannic acid–based chelation therapy in ferric citrate–supplemented rats

Jannarong Intakhad, Chalermchai Pilapong, Aiyarin Kittilukkana
Scientific Reports
Iron Metabolism and Disorders
article

Pharmacological evaluation of tannic acid–based chelation therapy in ferric citrate–supplemented rats

Jannarong Intakhad, Chalermchai Pilapong, Aiyarin Kittilukkana
article en

Abstract

Tannic acid is recognised as a natural iron chelator; however, its in vivo applicability may be constrained by non-specific interactions with amino- and thiol-containing biomolecules, potentially altering its bioavailability, pharmacokinetics and pharmacodynamics. In the present study, several formulations of tannic acid (TA)–based chelators, including unmodified TA, oxidised TA (TAox), phenylalanine-combined TA (TAphe), lysine-combined TA (TAlys), or cysteine-combined TA (TAcys), were synthesized and evaluated for chelation therapy in ferric citrate–supplemented rats. Animals fed a ferric citrate–enriched diet for eight weeks, followed by an eight-week chelation regimen with distinct TA-based formulations, exhibited chelator-dependent alterations in hepatic iron accumulation and liver enzyme activity, without significant changes in reactive oxygen species (ROS) production or lipid peroxidation. Notably, TAlys exhibited the greatest reduction in hepatic iron, while TAcys exhibited the greatest attenuation of serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) activities. In plasma, selected chelation treatments, particularly TAphe, reduced plasma ROS levels without affecting systemic iron accumulation. In contrast, none of the TA-based chelation treatments produced statistically significant changes in brain iron levels or oxidative stress markers, although some trends in specific behavioral performance were observed. Collectively, these findings indicate that TA-based chelation therapy predominantly modulates iron homeostasis and function. Specific TA-based formulations may therefore represent promising candidates for further pharmacological development in targeted iron chelation and related therapeutic or nutraceutical applications.

Scientific Reports
Chiang Mai University (TH)
Iron Metabolism and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon